Who are we?
Actelion is part of the Johnson & Johnson Family of Companies. We are leaders in the science and medicine of pulmonary arterial hypertension (PAH), with over 15 years of experience in this devastating cardiovascular disorder.
Drugs Disributed by Actelion Pharmaceuticals Israel Ltd
Nitrogen Mustard Analogue. Chlormethine (as HCl) 160 mcg/g. GEL: 60 gr.
For topic. dermat. use only. Apply a thin film of Chlormethine gel once dly. to affect. areas of the skin. Upon improve., tmt.with Chlormethine can be restarted at a reduced freq. of once every 3 d. If reintroduct. of tmt. is tolerated for at least one wk., the frequen. of applicat. can be incr. to every other day for at least 1 wk. and then to once dly. applicat. if tolerated. See lit.
Topical tmt. of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphom. in pts. who have received prior skin-directed ther.
Endothelin Receptor Antagonist. Macitentan 10 mg. F.C. TABS.: 30. 10 mg ×1/d, with or
without food, should be taken every
day at the same time.
Tmt. of PAH, who GROUP I to delay dis.
progress. Dis. progress. includ. : death,
initiat. of IV or subcutan. prostanoids, or
clin. worsening of PAH (decreased 6-min.
walk distance, worsened PAH sympt. and
need for additional PAH tmt.). The drug
also reduced hospitaliz. for PAH.
C/I: Hypersens., Preg., WOCBP who are
not using reliable contracep., Lact. Pts.
with severe hep. impair. (with or without
cirrhosis). Baseline values of hep.
aminotransferases (AST and/or ALT > 3 ×
Endothelin Receptor Antagonist. Bosentan 62.5 mg, 125 mg. F.C. TABS: 60 x 62.5 mg, 125 mg. Initial:
62.5 mg 2 x dly for 4 wks. Maint: 125 mg
2 x dly morn. and even. with or without
Prim. pulm. arterial hypertens. or second.
to scleroderma or other connect. tissue
dis. Reduct. number new digital ulcs. in
system. sclerosis, ongoing digital ulc. dis.
Selective IP Receptor Agonist. Selexipag 200, 400, 600, 800, 1000, 1200, 1400, 1600 mcg. TABS.: 60×200, 400, 600, 800, 1000, 1200, 1400, 1600 mcg
Individ. dose titrat. : Each patient should be up titrated to the highest individ. tolerated dose, which can range from 200 mcg given twice dly. to 1,600 mcg given twice dly. (individ. maint. dose). The recom. init. dose 200mcg given twice dly., approx. 12 hrs. apart. The dose is incr. in increm. of 200 mcg given twice dly., usually at wkly. intervals. In pts. in whom up titration was limited by reasons other than adr. reflect. the mode of action of Selexipag, a 2nd attempt to cont. up titrat. to the highest individ. tolerated dose up to a max. dose of 1,600 msg twice dly. may be considered. Individual. maint. dose. The highest tolerated dose reached during dose titrat. should be maint. . If the therapy over time is less tolerated at a given dose, symptomatic tmt. and/or a dose reduction to the next lower dose should be considered.
Long-term tmt. of pulmon.art. hypertens. (PAH) in adult pts. with WHO funct. class (FC) II–III, either as combin. ther. in pts. insuffic. control. with an endothelin receptor antag. (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhib., or as monother. in pts. who are not candidates for these therapies. Efficacy has been shown in a PAH population includ. idiopathic and heritable PAH, PAH assoc. with connective tissue disor., and PAH assoc. with corrected simple congen. heart dis.
C/I: Hypersens.. Severe coron. heart dis.or unstable angina. MI within the last 6 mnths. Decompens. cardiac fail.if not under close med. supervis. Severe arrhythmias. Cerebrovasc. events (e.g., TIA, stroke) within the last 3 mnths. Congen. or acquired valvular defects with clinical. relevant MI disord. not related to pulmon. hypertens.
Glucosylceramide Synthase Inhibitor. Miglustat 100 mg. CAPS: 84. Gaucher dis. Adults: Initial:
100 mg 3 x dly. Tempor. dose reduct. to
100 mg once/ twice a d. may be neces.
in some pts. because of diarrhoea.
Can be taken with/ without food.
Ped. popul. : The efficacy of Miglustat
in child. & adolesc. aged 0-17 yrs. with
type 1 Gaucher dis. has not been
Niemann-Pick type C dis.: Adult. –
Ped. popul. (pts. 12 yrs. and above)
Dosing in pts. under the age of 12 yrs.
should be adjust. on the basis of bdy.
surface. ar- See lit.
Oral tmt. of mild- moder. type 1 Gaucher
dis. Miglustat may be used only in the
tmt. of pts. for whom enzyme replac. ther.
Miglustat is indic. for the tmt. of progres.
neurological manifest. in adult pts. and
paed. pts. with Niemann-Pick type C dis.